Cheng-Shiun Leu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cheng-Shiun Leu has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Bruce Levin
Department of Biostatistics, Columbia University
3 shared publications - Joanne Ellen Mantell
Columbia University
3 shared publications - John Anton Joska
HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, Neuroscience Institute, University of Cape Town, Cape Town, South Africa
3 shared publications - Susie Hoffman
Department of Psychiatry, Columbia University, New York, USA
3 shared publications - Amita Gupta
Division of Infectious Diseases, School of Medicine, Johns Hopkins University , Baltimore, Maryland
2 shared publications - Andries Ehlers
Envisage IT Cape Town South Africa
2 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wolters Kluwer Health in Pediatric Emergency Care
Continuous Pulse Oximetry Analysis to Predict Outcomes in Young Infants With Bronchiolitis Presenting to the Emergency Department
Background: Predictive analytics using continuously measured vital signs from bedside monitors has improved outcomes in critically ill children. We investigated whether continuous pulse oximetry data collected during emergency department (ED) evaluation can identify infants ≤90 days old with bronchiolitis at low risk of respiratory deterioration. Methods: We conducted a single-center retrospective cohort study of infants ≤90 days old with bronchiolitis who presented to a tertiary-care pediatric ED from November 2021 to November 2025. Infants were identified using the ICD-10 code with manual eligibility confirmation. Heart rate and oxygen saturation features were generated from continuous pulse oximetry during the first 2 hours of ED evaluation. The primary outcome was respiratory deterioration within 24 hours of ED arrival, defined as initiation of high-flow nasal cannula, continuous/bilevel positive airway pressure, or invasive mechanical ventilation. Data were split into derivation and validation cohorts (70/30, stratified by outcome). An L2-regularized logistic regression model estimated the probability of respiratory deterioration, with a classification threshold selected to prioritize sensitivity. Results: Of 290 infants meeting clinical eligibility, 117 had sufficient continuous pulse oximetry data; 57 (49%) had respiratory deterioration. The primary model included 3 features: the median and interquartile range (IQR) of heart rate, and oxygen saturation IQR. In the validation cohort, the model showed moderate sensitivity (0.78, 95% CI: 0.58-0.95) and fair discrimination (AUROC=0.78, 95% CI: 0.62-0.93). Conclusion: We derived and validated a model using data from continuous pulse oximetry to identify low-risk infants with bronchiolitis. With further refinement and integration into monitor design systems, this approach may enhance clinical utility of continuous pulse oximetry.
- 19 October 2026
- Published by Wolters Kluwer Health in Pediatric Emergency Care
Open AccessContinuous Pulse Oximetry Analysis to Predict Outcomes in Young Infants With Bronchiolitis Presenting to the Emergency Department
Background: Predictive analytics using continuously measured vital signs from bedside monitors has improved outcomes in critically ill children. We investigated whether continuous pulse oximetry data collected during emergency department (ED) evaluation can identify infants ≤90 days old with bronchiolitis at low risk of respiratory deterioration. Methods: We conducted a single-center retrospective cohort study of infants ≤90 days old with bronchiolitis who presented to a tertiary-care pediatric ED from November 2021 to November 2025. Infants were identified using the ICD-10 code with manual eligibility confirmation. Heart rate and oxygen saturation features were generated from continuous pulse oximetry during the first 2 hours of ED evaluation. The primary outcome was respiratory deterioration within 24 hours of ED arrival, defined as initiation of high-flow nasal cannula, continuous/bilevel positive airway pressure, or invasive mechanical ventilation. Data were split into derivation and validation cohorts (70/30, stratified by outcome). An L2-regularized logistic regression model estimated the probability of respiratory deterioration, with a classification threshold selected to prioritize sensitivity. Results: Of 290 infants meeting clinical eligibility, 117 had sufficient continuous pulse oximetry data; 57 (49%) had respiratory deterioration. The primary model included 3 features: the median and interquartile range (IQR) of heart rate, and oxygen saturation IQR. In the validation cohort, the model showed moderate sensitivity (0.78, 95% CI: 0.58-0.95) and fair discrimination (AUROC=0.78, 95% CI: 0.62-0.93). Conclusion: We derived and validated a model using data from continuous pulse oximetry to identify low-risk infants with bronchiolitis. With further refinement and integration into monitor design systems, this approach may enhance clinical utility of continuous pulse oximetry.
The Epilepsy‐Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population‐based cohorts in the United States
Objective: With the expected demographic shift toward those ≥65 years of age in the United States, late onset epilepsy (LOE) poses a significant public health issue, yet it has been historically understudied. We are undertaking an effort in the Epilepsy‐Cog study to pool individual participant data from six United States‐based prospective cohort studies. In this paper, we outline the process for ascertaining epilepsy, harmonizing, and pooling individual participant data across the six cohorts. Methods: The Epilepsy‐Cog study includes individual participant data from six United States‐based longitudinal cohort studies: Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Multi‐Ethnic Study of Atherosclerosis, Northern Manhattan Study (NOMAS), Reasons for Geographic and Racial Differences in Stroke, and Washington Heights/Inwood Columbia Aging Project. In all cohorts except NOMAS, prevalent and incident epilepsy were ascertained using Medicare claims‐based algorithms. In NOMAS, epilepsy cases were identified through cohort‐based reporting and medical record review. To perform cross‐cohort harmonization of variables, we used the lowest common denominator approach, assigning response categories or value levels in common across all cohorts. Results: From a total of 68 544 participants across six cohorts, 43 753 participants met eligibility criteria for Epilepsy‐Cog. Among them, we identified 551 (1.3%) participants with prevalent epilepsy and 1500 (3.4%) participants with incident epilepsy. We have harmonized demographic characteristics, health behaviors, vascular risk factors (VRFs), one genetic variable, medication use, subjective health status measures, incident events, and cause‐of‐death variables. Significance: The Epilepsy‐Cog pooled cohort of 43 753 participants with and without epilepsy, combined with harmonized demographic, VRF, and event data, offers a unique resource to yield new insights into LOE.
The Epilepsy‐Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population‐based cohorts in the United States
Objective: With the expected demographic shift toward those ≥65 years of age in the United States, late onset epilepsy (LOE) poses a significant public health issue, yet it has been historically understudied. We are undertaking an effort in the Epilepsy‐Cog study to pool individual participant data from six United States‐based prospective cohort studies. In this paper, we outline the process for ascertaining epilepsy, harmonizing, and pooling individual participant data across the six cohorts. Methods: The Epilepsy‐Cog study includes individual participant data from six United States‐based longitudinal cohort studies: Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Multi‐Ethnic Study of Atherosclerosis, Northern Manhattan Study (NOMAS), Reasons for Geographic and Racial Differences in Stroke, and Washington Heights/Inwood Columbia Aging Project. In all cohorts except NOMAS, prevalent and incident epilepsy were ascertained using Medicare claims‐based algorithms. In NOMAS, epilepsy cases were identified through cohort‐based reporting and medical record review. To perform cross‐cohort harmonization of variables, we used the lowest common denominator approach, assigning response categories or value levels in common across all cohorts. Results: From a total of 68 544 participants across six cohorts, 43 753 participants met eligibility criteria for Epilepsy‐Cog. Among them, we identified 551 (1.3%) participants with prevalent epilepsy and 1500 (3.4%) participants with incident epilepsy. We have harmonized demographic characteristics, health behaviors, vascular risk factors (VRFs), one genetic variable, medication use, subjective health status measures, incident events, and cause‐of‐death variables. Significance: The Epilepsy‐Cog pooled cohort of 43 753 participants with and without epilepsy, combined with harmonized demographic, VRF, and event data, offers a unique resource to yield new insights into LOE.
- 30 October 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (1) , 102270
Implementation of an outpatient clinical pharmacy service at an adult cystic fibrosis center
- 30 October 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (1) , 102270
Implementation of an outpatient clinical pharmacy service at an adult cystic fibrosis center
- 14 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (20) , 1617-1620
Augmented Cardiac Inotropy by Phosphodiesterase Inhibition Requires Phosphorylation of Rad and Increased Calcium Current
- 14 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (20) , 1617-1620
Augmented Cardiac Inotropy by Phosphodiesterase Inhibition Requires Phosphorylation of Rad and Increased Calcium Current
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (4) , e011110
mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice
BACKGROUND: Mutations in LMNA encoding nuclear envelope proteins lamin A/C cause dilated cardiomyopathy. Activation of the AKT/mTOR (RAC-α serine/threonine-protein kinase/mammalian target of rapamycin) pathway is implicated as a potential pathophysiologic mechanism. The aim of this study was to assess whether pharmacological inhibition of mTOR signaling has beneficial effects on heart function and prolongs survival in a mouse model of the disease, after onset of heart failure. METHODS: We treated male Lmna H222P/H222P mice, after the onset of heart failure, with placebo or either of 2 orally bioavailable mTOR inhibitors: everolimus or NV-20494, a rapamycin analog highly selective against mTORC1. We examined left ventricular remodeling, and the cell biological, biochemical, and histopathologic features of cardiomyopathy, potential drug toxicity, and survival. RESULTS: Everolimus treatment (n=17) significantly reduced left ventricular dilatation and increased contractility on echocardiography, with a 7% ( P =0.018) reduction in left ventricular end-diastolic diameter and a 39% ( P =0.0159) increase fractional shortening compared with placebo (n=17) after 6 weeks of treatment. NV-20494 treatment (n=15) yielded similar but more modest and nonsignificant changes. Neither drug prevented the development of cardiac fibrosis. Drug treatment reactivated suppressed autophagy and inhibited mTORC1 signaling in the heart, although everolimus was more potent. With regards to drug toxicity, everolimus alone led to a modest degree of glucose intolerance during glucose challenge. Everolimus (n=20) and NV-20494 (n=20) significantly prolonged median survival in Lmna H222P/H222P mice, by 9% ( P =0.0348) and 11% ( P =0.0206), respectively, compared with placebo (n=20). CONCLUSIONS: These results suggest that mTOR inhibitors may be beneficial in patients with cardiomyopathy caused by LMNA mutations and that further study is warranted.
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (4) , e011110
Open AccessmTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice
BACKGROUND: Mutations in LMNA encoding nuclear envelope proteins lamin A/C cause dilated cardiomyopathy. Activation of the AKT/mTOR (RAC-α serine/threonine-protein kinase/mammalian target of rapamycin) pathway is implicated as a potential pathophysiologic mechanism. The aim of this study was to assess whether pharmacological inhibition of mTOR signaling has beneficial effects on heart function and prolongs survival in a mouse model of the disease, after onset of heart failure. METHODS: We treated male Lmna H222P/H222P mice, after the onset of heart failure, with placebo or either of 2 orally bioavailable mTOR inhibitors: everolimus or NV-20494, a rapamycin analog highly selective against mTORC1. We examined left ventricular remodeling, and the cell biological, biochemical, and histopathologic features of cardiomyopathy, potential drug toxicity, and survival. RESULTS: Everolimus treatment (n=17) significantly reduced left ventricular dilatation and increased contractility on echocardiography, with a 7% ( P =0.018) reduction in left ventricular end-diastolic diameter and a 39% ( P =0.0159) increase fractional shortening compared with placebo (n=17) after 6 weeks of treatment. NV-20494 treatment (n=15) yielded similar but more modest and nonsignificant changes. Neither drug prevented the development of cardiac fibrosis. Drug treatment reactivated suppressed autophagy and inhibited mTORC1 signaling in the heart, although everolimus was more potent. With regards to drug toxicity, everolimus alone led to a modest degree of glucose intolerance during glucose challenge. Everolimus (n=20) and NV-20494 (n=20) significantly prolonged median survival in Lmna H222P/H222P mice, by 9% ( P =0.0348) and 11% ( P =0.0206), respectively, compared with placebo (n=20). CONCLUSIONS: These results suggest that mTOR inhibitors may be beneficial in patients with cardiomyopathy caused by LMNA mutations and that further study is warranted.
- 12 June 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 145, 109289
Association of antiseizure medication adherence with illness perceptions in adults with epilepsy
- 12 June 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 145, 109289
Association of antiseizure medication adherence with illness perceptions in adults with epilepsy
- Open Access
- 24 March 2023
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 93 (4) , 327-332
Comparing Predictive Ability of Two Objective Adherence Measures in a Community-Based Cohort on Antiretroviral Therapy in South Africa: Tenofovir Diphosphate Concentrations and Electronic Adherence Monitors
Background: Electronic adherence (EA) and tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) are objective measures of antiretroviral therapy (ART) adherence. We characterized the association between these measures in a prospective cohort of persons with HIV (PWH) on ART. Setting: Four primary health clinics in Cape Town, South Africa. Methods: We enrolled 250 virally suppressed PWH receiving tenofovir-based ART. We collected EA data, monthly viral load, and TFV-DP in DBS for 12 months. We used logistic regression to estimate the adjusted odds ratio (aOR) and 95% confidence intervals (CIs) for future viral breakthrough (VB) (>400 copies/mL) for each adherence measure. Receiver operating characteristics (ROCs) provided the predictive power of these measures. Results: Participants had a median (IQR) age of 34 (27–42); 78% were women. Twenty-one (8%) developed VB. Logistic regression showed that when percent EA and TFV-DP concentrations increased, the odds of VB decreased. This relationship was consistent at the time of VB (aOR of 0.41 [95% CI: 0.25 to 0.66] for TFV-DP and aOR of 0.64 [95% CI: 0.54 to 0.76] for EA) and for up to 2 months before VB. Both adherence measures predicted future VB at both 1 month and 2 months before viral load measurement. Conclusion: We established that 2 objective adherence measures, EA and TFV-DP in DBS, have a positive association with, and are both strongly predictive of, VB in a community-based South African cohort on ART. Future research is needed to determine the feasibility of implementing these adherence measures in resource-limited settings to facilitate adherence interventions.
- 24 March 2023
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 93 (4) , 327-332
Open AccessComparing Predictive Ability of Two Objective Adherence Measures in a Community-Based Cohort on Antiretroviral Therapy in South Africa: Tenofovir Diphosphate Concentrations and Electronic Adherence Monitors
Background: Electronic adherence (EA) and tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) are objective measures of antiretroviral therapy (ART) adherence. We characterized the association between these measures in a prospective cohort of persons with HIV (PWH) on ART. Setting: Four primary health clinics in Cape Town, South Africa. Methods: We enrolled 250 virally suppressed PWH receiving tenofovir-based ART. We collected EA data, monthly viral load, and TFV-DP in DBS for 12 months. We used logistic regression to estimate the adjusted odds ratio (aOR) and 95% confidence intervals (CIs) for future viral breakthrough (VB) (>400 copies/mL) for each adherence measure. Receiver operating characteristics (ROCs) provided the predictive power of these measures. Results: Participants had a median (IQR) age of 34 (27–42); 78% were women. Twenty-one (8%) developed VB. Logistic regression showed that when percent EA and TFV-DP concentrations increased, the odds of VB decreased. This relationship was consistent at the time of VB (aOR of 0.41 [95% CI: 0.25 to 0.66] for TFV-DP and aOR of 0.64 [95% CI: 0.54 to 0.76] for EA) and for up to 2 months before VB. Both adherence measures predicted future VB at both 1 month and 2 months before viral load measurement. Conclusion: We established that 2 objective adherence measures, EA and TFV-DP in DBS, have a positive association with, and are both strongly predictive of, VB in a community-based South African cohort on ART. Future research is needed to determine the feasibility of implementing these adherence measures in resource-limited settings to facilitate adherence interventions.
- 2 October 2022
- Published by Taylor & Francis in Sequential Analysis
- Vol. 41 (4) , 451-491
Proof of a Key Inequality for Lattice Event Probabilities with Equal Odds
Levin and Leu ( 2021 Levin, B. and Leu, C.-S. (2021). A Key Inequality for Lower Bound Formulas for Lattice Event Probabilities. Sequential Analysis 40(4):554–574. doi:10.1080/07474946.2021.2010417 [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ) introduced some key inequalities that underlie the lower bound formula for the probability of lattice events when using adaptive members of the Levin-Robbins-Leu family of sequential subset selection procedures for binary outcomes. Here we provide a rigorous proof of the key inequality for each adaptive procedure in the special case of equal odds parameters. We also provide some further insight into why the key inequality holds for arbitrary odds parameters and we present a complete proof in that case for a simple yet non-trivial prototype example. Two errata in the abovementioned publication are also corrected herein.
- 2 October 2022
- Published by Taylor & Francis in Sequential Analysis
- Vol. 41 (4) , 451-491
Proof of a Key Inequality for Lattice Event Probabilities with Equal Odds
Levin and Leu ( 2021 Levin, B. and Leu, C.-S. (2021). A Key Inequality for Lower Bound Formulas for Lattice Event Probabilities. Sequential Analysis 40(4):554–574. doi:10.1080/07474946.2021.2010417 [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ) introduced some key inequalities that underlie the lower bound formula for the probability of lattice events when using adaptive members of the Levin-Robbins-Leu family of sequential subset selection procedures for binary outcomes. Here we provide a rigorous proof of the key inequality for each adaptive procedure in the special case of equal odds parameters. We also provide some further insight into why the key inequality holds for arbitrary odds parameters and we present a complete proof in that case for a simple yet non-trivial prototype example. Two errata in the abovementioned publication are also corrected herein.
- Open Access
- 1 July 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (13)
RRM1 variants cause a mitochondrial DNA maintenance disorder via impaired de novo nucleotide synthesis
Mitochondrial DNA (mtDNA) depletion/deletions syndromes (MDDS) encompass a clinically and etiologically heterogenous group of mitochondrial disorders caused by impaired mtDNA maintenance. Among the most frequent causes of MDDS are defects in nucleoside/nucleotide metabolism, which is critical for synthesis and homeostasis of the deoxynucleoside triphosphate (dNTP) substrates of mtDNA replication. A central enzyme for generating dNTPs is ribonucleotide reductase, a critical mediator of de novo nucleotide synthesis composed of catalytic RRM1 subunits in complex with RRM2 or p53R2. Here, we report 5 probands from 4 families who presented with ptosis and ophthalmoplegia as well as other clinical manifestations and multiple mtDNA deletions in muscle. We identified 3 RRM1 loss-of-function variants, including a dominant catalytic site variant (NP_001024.1: p.N427K) and 2 homozygous recessive variants at p.R381, which has evolutionarily conserved interactions with the specificity site. Atomistic molecular dynamics simulations indicate mechanisms by which RRM1 variants affect protein structure. Cultured primary skin fibroblasts of probands manifested mtDNA depletion under cycling conditions, indicating impaired de novo nucleotide synthesis. Fibroblasts also exhibited aberrant nucleoside diphosphate and dNTP pools and mtDNA ribonucleotide incorporation. Our data reveal that primary RRM1 deficiency and, by extension, impaired de novo nucleotide synthesis are causes of MDDS.
- 1 July 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (13)
Open AccessRRM1 variants cause a mitochondrial DNA maintenance disorder via impaired de novo nucleotide synthesis
Mitochondrial DNA (mtDNA) depletion/deletions syndromes (MDDS) encompass a clinically and etiologically heterogenous group of mitochondrial disorders caused by impaired mtDNA maintenance. Among the most frequent causes of MDDS are defects in nucleoside/nucleotide metabolism, which is critical for synthesis and homeostasis of the deoxynucleoside triphosphate (dNTP) substrates of mtDNA replication. A central enzyme for generating dNTPs is ribonucleotide reductase, a critical mediator of de novo nucleotide synthesis composed of catalytic RRM1 subunits in complex with RRM2 or p53R2. Here, we report 5 probands from 4 families who presented with ptosis and ophthalmoplegia as well as other clinical manifestations and multiple mtDNA deletions in muscle. We identified 3 RRM1 loss-of-function variants, including a dominant catalytic site variant (NP_001024.1: p.N427K) and 2 homozygous recessive variants at p.R381, which has evolutionarily conserved interactions with the specificity site. Atomistic molecular dynamics simulations indicate mechanisms by which RRM1 variants affect protein structure. Cultured primary skin fibroblasts of probands manifested mtDNA depletion under cycling conditions, indicating impaired de novo nucleotide synthesis. Fibroblasts also exhibited aberrant nucleoside diphosphate and dNTP pools and mtDNA ribonucleotide incorporation. Our data reveal that primary RRM1 deficiency and, by extension, impaired de novo nucleotide synthesis are causes of MDDS.
- 1 July 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , 669-674
Survival in cystic fibrosis after acute respiratory failure supported by extracorporeal membrane oxygenation and/or invasive mechanical ventilation
- 1 July 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , 669-674
Survival in cystic fibrosis after acute respiratory failure supported by extracorporeal membrane oxygenation and/or invasive mechanical ventilation